Abstract: Objective To compare the value of 18F-FDG PET/CT SUVmax before neoadjuvant chemotherapy, Ki-67, p53 and EGFR in predicting pathologic complete response(pCR) after neoadjuvant chemotherapy between triple-negative breast cancer(TNBC) and non-TNBC patients. Methods Twenty-seven cases were newly diagnosed TNBC patients and 184 cases were non-TNBC. 18F-FDG PET/CT was performed before neoadjuvant chemotherapy to measure the SUVmax. Before neoadjuvant chemotherapy, we took immumohistochemical examination of Ki-67, p53 and EGFR in breast cancer tissues and calculated the rate of pathologic complete response (pCR). Results SUVmax before neoadjuvant chemotherapy in TNBC patients was higher than that in non-TNBC patients(P=0.045); the pCR rate in TNBC patients was obviously higher than that in non-TNBC patients(P<0.001). In TNBC and non-TNBC patients, there was no statistical difference in SUVmax between achieved pCR group and non-achieved pCR group(P>0.05). There was no statistical difference in pCR rate between Ki-67, p53, EGFR positive groups and the negative groups (P>0.05). Conclusion TNBC is more sensitive than non-TNBC to neoadjuvant chemotherapy, and SUVmax before neoadjuvant chemotherapy in TNBC patients is higher than that in non-TNBC patients, which means TNBC has a higher metabolism. SUVmax, Ki-67, p53 and EGFR couldn't predict the pCR of TNBC or non-TNBC with neoadjuvant chemotherapy.